Knopman, D <br/><br/>
An open-label, 24-week pilot study of the methyl donor betaine in Alzheimer disease patients.  [electronic resource] 

 -  Alzheimer disease and associated disorders   
 - 162-5 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0893-0341 
<br/><br/><label>Standard No.: </label>10.1097/00002093-200107000-00008  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Aged<br/>Aged, 80 and over<br/>Alzheimer Disease--drug therapy<br/>Betaine--adverse effects<br/>Cognition Disorders--drug therapy<br/>Disease Progression<br/>Female<br/>Gastrointestinal Agents--adverse effects<br/>Homocysteine--metabolism<br/>Humans<br/>Male<br/>Mental Status Schedule<br/>Middle Aged<br/>Risk Factors<br/>Treatment Outcome